Public record
Glucagon: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Label
FDA label facts for glucagon
The FDA label read for glucagon (Gvoke HypoPen 0.5 mg Auto-Injector, application NDA212097) was last revised on 2026-09-30. It carries no boxed warning. Of the 4 population sections checked, 4 are present: pregnancy, lactation, pediatric use, geriatric use.
| Measure | Value | Note |
|---|---|---|
| Label revision date | 2026-09-30 | |
| Label read | Gvoke HypoPen 0.5 mg Auto-Injector | NDA212097, brand-name application |
| Boxed warning | No | |
| Pregnancy section | Present | |
| Lactation section | Present | |
| Pediatric use section | Present | |
| Geriatric use section | Present |
How this was calculated
Selected the most recently revised prescription label for this single ingredient from an original manufacturer, preferring a brand-name application. Checked which sections exist and quoted headings and sentences exactly as printed.
One label: the newest prescription label for single-ingredient glucagon from an original manufacturer
Read from one label. Labels for other brands, strengths or forms of the same ingredient can differ. A missing section heading does not mean there is no guidance. Read the full label before relying on it.
Medicare Part D
Medicare Part D spending on glucagon
Medicare Part D spending on glucagon products was $112.8M in 2024 across 242,348 claims, compared with $103.4M in 2023 (+9.0%). Average spending per claim was $465, before rebates.
| Measure | Value | Note |
|---|---|---|
| Total spending, 2024 | $112.8M | |
| Total spending, 2023 | $103.4M | |
| Change in spending, 2023 to 2024 | +9.0% | |
| Claims (prescription fills), 2024 | 242,348 | |
| Average spending per claim, 2024 | $465 | |
| Gvoke Hypopen 2-Pack: spending, 2024 | $48.3M | 73,745 claims |
| Baqsimi: spending, 2024 | $21.5M | 43,157 claims |
| Glucagon Emergency Kit: spending, 2024 | $19.0M | 69,133 claims |
How this was calculated
Summed total spending and claims over every brand and generic row with this generic name in the CMS file, using the Overall manufacturer rows. Combination products excluded. Average per claim is spending divided by claims.
Every single-ingredient glucagon product in Part D (Gvoke Hypopen 2-Pack, Baqsimi, Glucagon Emergency Kit), 2024.
Gross drug cost before manufacturer rebates, so net cost is lower. Part D excludes some uses by law (for example erectile dysfunction, weight loss and hair growth), so claims reflect covered uses only. Compounded products are not included.
Articles on Glucagon
- Triple Agonists (GLP-1/GIP/Glucagon) Titration and Tapering Algorithms
- Triple Agonists (GLP-1/GIP/Glucagon) Adverse-Event Management Protocols
- Triple Agonists (GLP-1/GIP/Glucagon) Billing & Prior-Auth Playbook
- Triple Agonists (GLP-1/GIP/Glucagon) Class Overview Monograph
- Triple Agonists (GLP-1/GIP/Glucagon) Special-Populations Summary
- Triple Agonists (GLP-1/GIP/Glucagon): How to Select the Right Agent Within the Class